NCT03412799 - Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 4, 2018

Primary Completion Date

February 28, 2022

Study Completion Date

February 28, 2022

Conditions

Pancreatic Cancer MetastaticPancreatic Cancer Stage IVStage IV Pancreatic Cancer

Interventions

DRUG

SBP-101

Administered as subcutaneous (SC) injection, escalating dose cohorts

DRUG

nab-paclitaxel

Administered as intravenous (IV) infusion

DRUG

Gemcitabine Injection

Administered as intravenous (IV) infusion

Trial Locations (7)

Blacktown Cancer & Haematology Centre, Blacktown

Austin Health, Heidelberg

John Flynn Private Hospital, Tugun

Ashford Cancer Centre, Kurralta Park

University of Rochester Medical Center, Rochester

University of Florida, Gainesville

Scripps MD Anderson Cancer Center, La Jolla